BioSpace News Archive

Helsinn Group announces the signing of a new financing agreement with BancaStato, effective from September 2023.

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced top line data from two abstracts being presented at the 15th World Stroke Congress held October 10-12, 2023, in Toronto, Canada on the possible role of nVNS in the treatment of acute neurological injuries.

Pacira BioSciences, Inc., the industry leader in its commitment to non-opioid pain management and regenerative health solutions, announced the appointments of Marcelo Bigal, MD, PhD, Abraham Ceesay, Michael Yang, and Alethia Young, to its Board of Directors effective immediately.

Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) has previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic.

ValGenesis, Inc and Valspec, a global provider of system validation and lifecycle services, have partnered to extend a suite of sophisticated ValGenesis products for life sciences clients in the U.S.

Mapi Pharma Ltd. announced that recent clinical data from studies of GA Depot 40 mg will be presented at the forthcoming European Committee for Treatment and Research in Multiple Sclerosis & Americas Committee for Treatment and Research in Multiple Sclerosis meeting to take place in Milan, Italy, October 11 to 13.

Eckert & Ziegler and PharmaLogic Holdings Corp. have signed a reservation agreement for the supply of the therapeutic radioisotope Actinium-225.

Shuttle Pharmaceuticals Holdings, Inc. announced that Dr. Anatoly Dritschilo, Chief Executive Officer, will present and host one-on-one meetings with investors at the Lytham Partners Fall 2023 Investor Conference, taking place virtually on October 17, 2023.

Amylyx Pharmaceuticals, Inc. (Nasdaq: AMLX) (“Amylyx” or the “Company”) today announced the publication of a post hoc analysis in the peer-reviewed medical journal, Annals of Clinical and Translational Neurology comparing the long term survival of participants in the CENTAUR study versus a historical clinical trial control group.

IRLAB Therapeutics (STO:IRLAB-A)(FRA:6IRA) Gothenburg, Sweden, October 10, 2023 - IRLAB Therapeutics AB (Nasdaq Stockholm:IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will present at Redeye Neurology Theme Event on Wednesday, October 11, 2023.